Over 90% of domestic imitated drugs are sold with gold, which hinders the innovation and development of pharmaceutical enterprises

[market analysis of chinapharma.com] in recent years, pharmaceutical companies have released annual reports From the annual reports released by enterprises, some pharmaceutical companies' sales expenses account for more than 40% of their revenue Correspondingly, the proportion of R & D investment is relatively small Guo yunpei, President of China Pharmaceutical Enterprise Management Association, said that at present, the proportion of the whole pharmaceutical sales of Chinese pharmaceutical enterprises is very high, which is much higher than the level of foreign countries It is estimated that the cost of "bringing gold" sales will not be less (more than 90% of the domestic imitated drugs have been sold with gold, which has become the key picture source of hindering the innovation and development of pharmaceutical enterprises Baidu pictures) the "gold with gold" sales, which hinders the innovation and development of pharmaceutical enterprises, has become the "common fault" of most domestic pharmaceutical enterprises According to the data of tonghuashun, in 2015, 202 listed companies in the pharmaceutical and biological industry achieved an operating revenue of 784.47 billion yuan, while the sales expense reached 100.287 billion yuan, accounting for 12.78% of the operating revenue It is worth noting that in 2015, the sales expenses of 42 listed companies accounted for more than 30% of the operating revenue In 2016, the pharmaceutical and biological industry continued this trend For example, in 2016, Cr 39 achieved an operating revenue of 8.982 billion yuan, a net profit of 1.198 billion yuan, and a sales expense of 3.279 billion yuan, accounting for 36.72% of its revenue The sales expense has far exceeded the net profit, while the R & D expenditure is only 280 million yuan, accounting for 3.12% In addition, the operating revenue of Harbin Pharmaceutical Co., Ltd in 2016 was 14.127 billion yuan, the net profit was 788 million yuan, and the sales expense was 762 million yuan, basically the same as the net profit The R & D expenditure was only 183 million yuan, accounting for 1.29% In terms of the composition of marketing expenses of listed pharmaceutical enterprises, there are many items listed Common expenses include personnel compensation, market expenses, conference expenses, business (entertainment) expenses, travel expenses, advertising (publicity) expenses and transportation expenses Huang Donglin, industry research consultant of pharmaceutical manager, pointed out that the obviously high cost of sales is the hotbed of drug kickbacks, while the inefficient marketing mode has greatly restricted the normal development and innovative behavior of many pharmaceutical enterprises It can also be seen from the above examples that while the sales expenses of Chinese pharmaceutical enterprises are high, the corresponding R & D expenditure is low According to the research results report of "building a more standardized and valuable clinical academic exchange system in China's pharmaceutical industry" released on March 24, the R & D expenses of foreign innovative pharmaceutical enterprises usually account for more than 10% of the sales revenue of enterprises, but the figure of most pharmaceutical enterprises in China is often less than 5% Ding Lihua, general manager of Sinopharm, pointed out that China's drug market is the second largest in the world But more than 95% of the drugs in China are imitations, and less than 5% of the products have brands Wu Bin, vice president of China Pharmaceutical Business Association, said the core problem was overcapacity "The industrial policy has led to a large number of pharmaceutical factories in China from all levels, and the excessive industrial park of pharmaceutical production capacity has led to a difficult life for all enterprises In addition, the pharmaceutical enterprises in China lack of innovative genes, and a large number of generic drugs flood the market Some enterprises have taken chaotic measures if they want to survive in the market." These means include "bring gold" sales and so on The purpose is also to "stand out" in many generic drugs In Huang Donglin's view, the "business model" of "bringing gold" sales needs to stimulate doctors to prescribe prescriptions through kickbacks or other benefits, so that enterprises ignore or even give up evidence-based medicine research and clinical research Its further negative impact is that enterprises need to pay more for drug kickbacks and "cash" sales, and then reduce investment in R & D innovation, eventually forming a vicious circle and hindering their own innovative behavior To promote the reform and promote the survival of the fittest, the target of "bringing money" for medical representatives is doctors, so why do doctors take bribes from medical representatives? Wang Yuan believes that this is related to the current salary level of doctors "We doctors who go out of the clinic, 5 years of University plus 6 years of working experience, can obtain the qualification of attending physician, and can go out of the clinic alone This is 11 years later But now the registration fee is only a few yuan Even if it is increased five times, it will be about 20 yuan " Wang Yuan said that the income of a hairdresser is higher than that of a doctor's clinic Wang Yuan believes that although doctors don't get the income matching their own work, they can't take back the deduction, which can't be considered as a "reasonable compensation" for doctors' income, but should reform the doctor's salary system Huang Donglin also said that drug rebate is a kind of behavior contrary to industry ethics and national laws and regulations, so it can not be defined as a "reasonable compensation" What's more, drug kickbacks provide clinicians with "reasonable income compensation" by inducing prescriptions rather than according to the real treatment purpose, which will promote or aggravate the unreasonable or unnecessary use of drugs in clinical practice, cause over prescription or wrong prescription, produce unnecessary treatment cost and may affect the actual treatment effect Cai Jiangnan, director of the center for health management and policy of CEIBS, told reporters that at present, the price of medical treatment is seriously low In this case, the situation of medical care with medicine and medical care with inspection also arises The reform of public hospitals is needed to liberate the productivity of doctors Only by adjusting the seriously low price of medical services can we establish a reasonable price formation mechanism In addition, for the issue of drug rebate, the report suggests that the medium-term and short-term prescriptions are to strengthen industry supervision, while the long-term prescriptions are in the supply side structural reform The low level and disordered competition in the pharmaceutical industry are the main hotbeds of drug kickbacks and commercial bribery, and the unreasonable drug pricing is the main reason to promote the spread of drug kickbacks and commercial bribery in the Chinese pharmaceutical market In addition, in addition to some pharmaceutical enterprises, all kinds of drug "distributors" also promote the generation of kickbacks and "cash" sales problems In order to fundamentally put an end to drug kickbacks and "gold carrying" sales, the report suggests that the pharmaceutical industry needs to carry out a structural adjustment from the inside, to enhance the overall competitiveness of products in the Chinese pharmaceutical market through the supply side structural reform, to clean up the drugs lacking in value, to put an end to the factors resulting in kickbacks in the circulation link, and to the virtual high in the payment link This will be the fundamental way to curb kickbacks and "belt gold" sales.